[Evaluation and management of insomnia in clinical practice and in the time of CoViD-19 in Italy: expert consensus and task-force recommendations from five scientific societies]. / Valutazione e trattamento dell'insonnia nella pratica clinica e ai tempi di CoViD-19 in Italia: raccomandazioni del panel di esperti e della task-force integrata di cinque società scientifiche.
Riv Psichiatr
; 55(6): 337-341, 2020.
Article
in Italian
| MEDLINE | ID: covidwho-992941
ABSTRACT
Insomnia symptoms might affect about 60% of the Italian population. Insomnia is a "24 hours syndrome" and a risk factor for medical and mental disorders. It should always be assessed and treated in the clinical practice. Cognitive Behavioral Therapy for Insomnia is the first line treatment but its availability in Italy is scarce. Pharmacological options in Italy are melatonin 2 mg prolonged release that should be the first choice in subjects ≥55 years old and used until 13 weeks; and for a short term use (≤4 weeks) Z-drugs or short-acting benzodiazepines (in subjects <65 years old) or a sedating antidepressant.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Consensus
/
Epidemics
/
Sleep Aids, Pharmaceutical
/
SARS-CoV-2
/
COVID-19
/
Sleep Initiation and Maintenance Disorders
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Humans
/
Middle aged
Country/Region as subject:
Europa
Language:
Italian
Journal:
Riv Psichiatr
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS